MX2023013734A - Terapia oral con undecanoato de testosterona preferida para lograr el tratamiento de reemplazo de testosterona. - Google Patents
Terapia oral con undecanoato de testosterona preferida para lograr el tratamiento de reemplazo de testosterona.Info
- Publication number
- MX2023013734A MX2023013734A MX2023013734A MX2023013734A MX2023013734A MX 2023013734 A MX2023013734 A MX 2023013734A MX 2023013734 A MX2023013734 A MX 2023013734A MX 2023013734 A MX2023013734 A MX 2023013734A MX 2023013734 A MX2023013734 A MX 2023013734A
- Authority
- MX
- Mexico
- Prior art keywords
- testosterone
- achieve
- preferred oral
- replacement treatment
- undecanoate therapy
- Prior art date
Links
- 229960000746 testosterone undecanoate Drugs 0.000 title abstract 4
- UDSFVOAUHKGBEK-CNQKSJKFSA-N testosterone undecanoate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](OC(=O)CCCCCCCCCC)[C@@]1(C)CC2 UDSFVOAUHKGBEK-CNQKSJKFSA-N 0.000 title abstract 4
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 title 2
- 229960003604 testosterone Drugs 0.000 title 1
- 238000002560 therapeutic procedure Methods 0.000 title 1
- 238000009165 androgen replacement therapy Methods 0.000 abstract 1
- 229940075999 phytosterol ester Drugs 0.000 abstract 1
- 229940068065 phytosterols Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/28—Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/26—Androgens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Inorganic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163190609P | 2021-05-19 | 2021-05-19 | |
| PCT/US2022/029819 WO2022245933A1 (en) | 2021-05-19 | 2022-05-18 | Preferred oral testosterone undecanoate therapy to achieve testosterone replacement treatment |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023013734A true MX2023013734A (es) | 2024-02-07 |
Family
ID=84140782
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023013734A MX2023013734A (es) | 2021-05-19 | 2022-05-18 | Terapia oral con undecanoato de testosterona preferida para lograr el tratamiento de reemplazo de testosterona. |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20230398128A1 (https=) |
| EP (1) | EP4340846A4 (https=) |
| JP (1) | JP2024521127A (https=) |
| KR (1) | KR20240027602A (https=) |
| AU (2) | AU2022277557B2 (https=) |
| BR (1) | BR112023024162A2 (https=) |
| CA (1) | CA3219547A1 (https=) |
| IL (1) | IL308658A (https=) |
| MX (1) | MX2023013734A (https=) |
| WO (1) | WO2022245933A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL2519230T3 (pl) | 2009-12-31 | 2019-05-31 | Marius Pharmaceuticals Llc | Modulacja rozpuszczalności, stabilności, absorpcji, metabolizmu i profilu farmakokinetycznego leków lipofilowych przez sterole |
| EP2968137B1 (en) | 2013-03-15 | 2021-11-10 | Marius Pharmaceuticals LLC | Emulsion formulations |
| US12403146B2 (en) | 2019-10-30 | 2025-09-02 | Marius Pharmaceuticals, Inc. | Preferred oral testosterone undecanoate therapy to achieve testosterone replacement treatment |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL2519230T3 (pl) * | 2009-12-31 | 2019-05-31 | Marius Pharmaceuticals Llc | Modulacja rozpuszczalności, stabilności, absorpcji, metabolizmu i profilu farmakokinetycznego leków lipofilowych przez sterole |
| US20200197412A1 (en) * | 2018-12-20 | 2020-06-25 | Clarus Therapeutics, Inc. | Methods of treating testosterone deficiency |
| US11564933B2 (en) * | 2019-04-12 | 2023-01-31 | Tolmar, Inc. | Methods of treating testosterone deficiency |
-
2022
- 2022-05-18 KR KR1020237043696A patent/KR20240027602A/ko active Pending
- 2022-05-18 MX MX2023013734A patent/MX2023013734A/es unknown
- 2022-05-18 JP JP2023572110A patent/JP2024521127A/ja active Pending
- 2022-05-18 AU AU2022277557A patent/AU2022277557B2/en active Active
- 2022-05-18 BR BR112023024162A patent/BR112023024162A2/pt not_active Application Discontinuation
- 2022-05-18 EP EP22805390.6A patent/EP4340846A4/en active Pending
- 2022-05-18 CA CA3219547A patent/CA3219547A1/en active Pending
- 2022-05-18 WO PCT/US2022/029819 patent/WO2022245933A1/en not_active Ceased
- 2022-05-18 IL IL308658A patent/IL308658A/en unknown
-
2023
- 2023-05-24 US US18/201,498 patent/US20230398128A1/en active Pending
-
2024
- 2024-10-31 AU AU2024227786A patent/AU2024227786A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2022277557A1 (en) | 2023-06-08 |
| JP2024521127A (ja) | 2024-05-28 |
| AU2024227786A1 (en) | 2024-11-21 |
| CA3219547A1 (en) | 2022-11-24 |
| WO2022245933A1 (en) | 2022-11-24 |
| IL308658A (en) | 2024-01-01 |
| KR20240027602A (ko) | 2024-03-04 |
| EP4340846A1 (en) | 2024-03-27 |
| WO2022245933A8 (en) | 2023-01-26 |
| US20230398128A1 (en) | 2023-12-14 |
| BR112023024162A2 (pt) | 2024-02-06 |
| EP4340846A4 (en) | 2025-04-02 |
| AU2022277557B2 (en) | 2024-08-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2023013734A (es) | Terapia oral con undecanoato de testosterona preferida para lograr el tratamiento de reemplazo de testosterona. | |
| MX2024006123A (es) | Triptaminas especificas para usarse en el tratamiento de trastornos de estado de animo. | |
| MX2022007968A (es) | Dosificacion de gamma-hidroxibutirato (ghb). | |
| MX2020011234A (es) | Moduladores de receptor similar al dominio de oligomerizacion de union a nucleotidos que contiene dominio de pirina 3 (nlrp3). | |
| MX2009009761A (es) | Composiciones y estuches para tratamiento de la influenza. | |
| GEAP201914679A (en) | New aminoacid derivatives, a process for their preparation and pharmaceutical compositions containing them | |
| GEP20207160B (en) | New piperidinyl derivatives, a process for their preparation and pharmaceutical compositions containing them | |
| MX348481B (es) | Productos quimicos, composiciones y metodos para tratamiento y prevencion de infecciones de virus orthopox y enfermedades asociadas. | |
| NI201100162A (es) | Derivados de indol como antagonistas del receptor crth2 | |
| PA8799401A1 (es) | Uso de un beta bloqueante para la fabricacion de un medicamento para el tratamiento de los hemangiomas | |
| GEAP201914680A (en) | New hydroxyacid derivatives, a process for their preparation and pharmaceutical compositions containing them | |
| NZ737399A (en) | Ccr2 modulators | |
| UA98839C2 (en) | N,n-disubstituted aminoalkylbiphenyl antagonists of prostaglandin d2 receptors | |
| MX2009006202A (es) | Composiciones y metodos para el tratamiento de neoplasma. | |
| SG10201909060SA (en) | Substituted 2-anilinopyrimidine derivatives as egfr modulators | |
| MX2013000958A (es) | Fabricación del inhibidor-inter-alfa (iaip) a partir de plasma. | |
| SG10201810928SA (en) | Novel antitumoral use of cabazitaxel | |
| MX2010006204A (es) | Derivados de oxindol 5,6-disubstituidos y el uso de los mismos para el tratamiento de enfermedades dependientes de la vasopresina. | |
| MY201080A (en) | Nlrp3 modulators | |
| MX2010006206A (es) | Derivados de oxindol substituidos por 5-halogeno y el uso de los mismos para el tratamiento de enfermedades dependientes de la vasopresina. | |
| IL290177A (en) | History of 4,2,1-oxadiazol-5-one for cancer therapy | |
| GEP20247585B (en) | Furoindazole derivatives | |
| PH12020551018A1 (en) | Oral delivery of glp-1 peptide analogs | |
| PH12017550077A1 (en) | C-3 novel triterpenone with c-17 reverse amide derivatives as hiv inhibitors | |
| GB201302343D0 (en) | Pharmaceutical compositions comprising 15-OHEPA and methods for using the same |